Novartis Files for Arbitration with ICC, Claiming No Obligation to Pay Certain Royalties for Fingolimod to Mitsubishi Tanabe

Novartis Pharma AG has filed for arbitration against Mitsubishi Tanabe Pharma with the International Chamber of Commerce (ICC) claiming that the company is not obligated to pay certain royalties on sales of the multiple sclerosis treatment fingolimod, the Japanese company...read more